Newsbenzinga
Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…